Results 241 to 250 of about 42,597 (297)

Changes in the Prevalence of Antimalarial Partner Drug Resistance Markers and Policy in 6 Sub-Saharan African Countries From 2000 to 2021: A Systematic Review. [PDF]

Open Forum Infect Dis
Walker A, Ross A, Nsanzabana C.
europepmc   +1 more source

Pharmacometric evaluation of amodiaquine-sulfadoxine-pyrimethamine and dihydroartemisinin-piperaquine seasonal malaria chemoprevention in northern Uganda

Bonnington C, Nuwa A, Theiss-Nyland K, Kajubi R, Kamya MR, Nankabirwa J, Ebong C, Rassi C, Nabakooza J, Opigo J, Salandindi D, Odongo M, Sararat C, Watson JA, Suwannasin K, Proux S, Koesukwiwat U, Tarning J, Imwong M, Tibenderana J, Nosten F, White N.   +21 more
europepmc   +1 more source

Tracking Plasmodium falciparum antimalarial resistance markers during a malaria pre-elimination period in the Pacific coast of South America. [PDF]

Sci Rep
Ñacata I, Early AM, Boboy J, Neafsey DE, Sáenz FE.   +4 more
europepmc   +1 more source

Prevalence of Plasmodium falciparum parasites harbouring chloroquine-resistant but not artemisinin-resistant alleles in Busia County, Western Kenya. [PDF]

Malar J
Onchieku NM, Gesusu N, Caspar E, Karani L, Thiong'o K, Kamau L, Kiboi D, Thiebaut L, Ma L, Kimani F, Matoke-Muhia D, Ménard D.   +11 more
europepmc   +1 more source

Impact of dhps mutations on sulfadoxine-pyrimethamine protective efficacy and implications for malaria chemoprevention. [PDF]

Nat Commun
Mousa A, Cuomo-Dannenburg G, Thompson HA, Bell DJ, D'Alessandro U, Gosling R, Nahum A, Barnes KI, Raman J, Workmann L, Foo YS, Flegg JA, Hocke EF, Hansson H, Chopo-Pizarro A, Beshir KB, Alifrangis M, Chico RM, Sutherland CJ, Okell LC, Roper C.   +20 more
europepmc   +1 more source

Effect of knowledge of sulfadoxine-pyrimethamine (SP) as prophylaxis for malaria on its uptake for intermittent preventive treatment of malaria in pregnancy (IPTp): Application of inverse probability weighted regression adjustment (IPWRA) technique. [PDF]

PLoS One
Natuhamya C, Mwebesa E, Tumwesigye NM.
europepmc   +1 more source

Clinically applicable parasite viability assay for rapid assessment of antimalarial pharmacodynamic endpoints. [PDF]

Antimicrob Agents Chemother
Maiga M, Wicha SG, Diallo F, Traoré I, Samaké AK, Sogore F, Diakité O, Dao F, Diallo D, Traoré A, Djimde AA, Spangenberg T, Demarta-Gatsi C, Dembele L.   +13 more
europepmc   +1 more source

Genome sequencing of Plasmodium malariae identifies continental segregation and mutations associated with reduced pyrimethamine susceptibility. [PDF]

Nat Commun
Ibrahim A, Mohring F, Manko E, van Schalkwyk DA, Phelan JE, Nolder D, Borrmann S, Adegnika AA, Di Santi SM, Alam MS, Mondal D, Nosten F, Sutherland CJ, Moon RW, Clark TG, Campino S.   +15 more
europepmc   +1 more source

Projected uptake of sulfadoxine-pyrimethamine for perennial malaria chemoprevention in children under 2 years of age in nine sub-Saharan African countries: an epidemiologically-based 5-year forecast analysis. [PDF]

Malar J
Audibert C, Hugo P, Gosling R, Eddis C, Center M, Tchouatieu AM.   +5 more
europepmc   +1 more source

Weekly dihydroartemisinin-piperaquine versus monthly sulfadoxine-pyrimethamine for malaria chemoprevention in children with sickle cell anaemia in Uganda and Malawi (CHEMCHA): a randomised, double-blind, placebo-controlled trial.

Lancet Infect Dis
Idro R, Nkosi-Gondwe T, Opoka R, Ssenkusu JM, Dennis K, Tsirizani L, Akun P, Rujumba J, Nambatya W, Kamya C, Phiri N, Joanita K, Komata R, Innussa M, Tenywa E, John CC, Tarning J, Denti P, Wasmann RE, Ter Kuile FO, Robberstad B, Phiri KS.   +21 more
europepmc   +1 more source